(Q40408341)

20 September 2017

title

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia (English)

1 reference

20 September 2017

1 reference

1 reference

acute myeloid leukemia

1 reference

Gail J Roboz

1

1 reference

20 September 2017

Ellen K Ritchie

2

1 reference

20 September 2017

Tania Curcio

3

1 reference

20 September 2017

Juliette Provenzano

4

1 reference

20 September 2017

Rebecca Carlin

5

1 reference

20 September 2017

Michael Samuel

6

1 reference

20 September 2017

Beth Wittenberg

7

1 reference

20 September 2017

Madhu Mazumdar

8

1 reference

20 September 2017

Paul J Christos

9

1 reference

20 September 2017

Susan Mathew

10

1 reference

20 September 2017

Sandra Allen-Bard

11

1 reference

20 September 2017

Eric J Feldman

12

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

20 September 2017

1 reference

20 September 2017

volume

113

1 reference

20 September 2017

issue

9

1 reference

20 September 2017

page(s)

2504-2511

1 reference

Age and acute myeloid leukemia

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Treatment of acute myeloid leukemia in older patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

The outcomes and costs of acute myeloid leukemia among the elderly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Treatment of older patients with acute myeloid leukemia--new agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23855

7 January 2021

Identifiers

DOI

10.1002/CNCR.23855

1 reference

20 September 2017

1 reference